Souhaitez-vous accéder aux communiqués récents ?

The annual general meeting was held on April 5, 2017 at the Company's offices at Lilleakerveien 2C, 0283 Oslo. Please find minutes of the meeting attached. ### For further information...

Reference is made to the notice published on 15 March 2017 regarding the annual general meeting in Targovax ASA (the "Company") to be held on 5 April 2017 at 10:00 am (CEST). The proposal by the...

Oslo, Norway, 4 April 2017: The Board of Directors of Targovax ASA (the "Company") has resolved to grant 172,000 options to subscribe for shares in the Company to employees under the Company's long...

Oslo, Norway, 23 March 2017: Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target treatment-resistant solid tumors,...

Reference is made to the stock exchange announcement made on 17 March 2017 regarding Targovax ASA's ("Targovax" or the "Company") resolution to apply for a transfer of the listing of the Company's...

Reference is made to the stock exchange announcement made on 17 March 2017 regarding Targovax ASA's ("Targovax" or the "Company") resolution to apply for a transfer of the listing of the Company's...

The board of directors of Targovax ASA has resolved to send an application to transfer the listing of the company's shares from Oslo Axess to Oslo Stock Exchange main list. The application will be...

The Annual General Meeting of Targovax ASA will be held at the Company's offices at Lysaker, on 5 April 2017 at 10:00 CET. Please find the notice including agenda for the General Meeting and...

On 15 March 2017, the Board of Directors of Targovax ASA approved the financial statements for 2016 for issuance, subject to approval by the Annual General meeting on April 5, 2017. Please find...

Oslo, Norway, 6 March 2017: Targovax ASA ("Targovax" or "the Company"; OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target, primarily, treatment-resistant...